Journal of General Internal Medicine

, Volume 28, Issue 7, pp 930–937 | Cite as

Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease

  • Andrew J. Gawron
  • John E. Pandolfino
  • Scott Miskevics
  • Sherri L. LaVela
Original Research



Empiric proton pump inhibitor use is common for gastroesophageal reflux disease (GERD), but initial proton pump inhibitor (PPI) prescription patterns in Veterans are unknown.


The study aims were to determine initial PPI prescriptions in Veterans diagnosed with GERD, and to characterize subsequent PPI use over the 2 years following initial prescription.


We conducted a retrospective study using Veteran’s Administration (VA) administrative data and chart review.


Patients diagnosed with GERD and provided an initial PPI prescription at Hines VA Hospital from 2003 to 2007, with 2 year follow-up for each patient (through 2009).


Initial PPI prescriptions were categorized as standard total daily dose or high total daily dose, and accuracy was confirmed by manual chart review. Descriptive statistics were calculated and bivariate analyses were used to assess for differences in demographics, prescriptions, and subsequent use by initial PPI dosage category.


Of the 1,621 patients included in the study, 378 (23.3 %) had high total daily dose initial PPI prescriptions and 1,243 (76.7 %) patients had standard total daily dose initial prescriptions. The majority of patients (65.8 %) received a 90-day or greater initial prescription. Over the 2 years following the initial PPI prescription, 13.0 % of patients with initial standard daily dose prescriptions had evidence of step-up therapy. Only 7.1 % of patients with initial high daily dose PPI prescriptions had evidence of step-down therapy. A large majority of patients (83.8 %) had at least one refill over 2 years, and the overall medication possession ratio was 0.86.


Many Veterans receive high total daily dose PPI prescriptions as initial therapy for a GERD diagnosis, and few patients have evidence for cessation or reduction of therapy. These results provide detailed data on prescribing and use of PPIs to help guide efforts for optimal PPI use in US Veterans.


drug GERD prescriptions Veteran Health Affairs 



Gastroesophageal reflux disease


Proton pump inhibitor


Histamine receptor 2 antagonists


Veteran’s administration


Non-steroidal anti-inflammatory drug


Decision support system


National data extracts


Medication possession ratio


Computerized clinical reminders


American Board of Internal Medicine


American Gastroenterology Association



We would like to acknowledge Dr. Elizabeth Tarlov, Ph.D. (VA Information Resource Center (VIReC), Edward Hines Jr. VA) for her assistance with defining measures from the VA pharmacy data set.

This work was directly funded by a VA HSR&D grant (LIP#42-131) provided through the Center for Management of Complex Chronic Care (co-PIs: Drs. Gawron and LaVela). Dr. Gawron is a National Research Service Award postdoctoral fellow at the Center for Healthcare studies under an institutional award from the Agency for Healthcare Research and Quality, T-32 HS 000078 (PI: Jane L. Holl, MD MPH).

Portions of this work were previously presented in abstract form (oral presentation) at Digestive Disease Week (May 2012, San Diego, CA).

Conflict of Interest

This material is based on work supported by the Office of Research and Development, Health Services Research and Development of the Department of Veterans Affairs. This paper reflects only the authors’ opinions and does not necessarily reflect the official position of the Department of Veterans Affairs. Dr. Pandolfino serves as a consultant for Given, Sandhill, and Shire, and on the advisory board for Crospon. None of the authors have a financial or other relationship that might signify a direct conflict of interest.


  1. 1.
    Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterol. 2009;136:376–386.CrossRefGoogle Scholar
  2. 2.
    Caro JJ, Salas M, Ward A. Healing and Relapse Rates in Gastroesophageal Reflux Disease Treated with the Newer Proton-Pump Inhibitors Lansoprazole, Rabeprazole, and Pantoprazole Compared with Omeprazole, Ranitidine, and Placebo: Evidence from Randomized Clinical Trials. Clin Ther. 2001;23:998–1017.PubMedCrossRefGoogle Scholar
  3. 3.
    Weijenborg PW, Cremonini F, Smout AJ, et al. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24:747–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterol. 2008;135:1383–1391.CrossRefGoogle Scholar
  5. 5.
    Heidelbaugh JJ, Goldberg KL, Inadomi JM, Suppl. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl):S27–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25:333–340.PubMedCrossRefGoogle Scholar
  7. 7.
    Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16:e228–34.PubMedGoogle Scholar
  8. 8.
    Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772–778.PubMedCrossRefGoogle Scholar
  9. 9.
    Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170:765–771.PubMedCrossRefGoogle Scholar
  11. 11.
    Kahrilas P. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359:1700–1707.PubMedCrossRefGoogle Scholar
  12. 12.
    American Gastroenterological Association. Choosing Wisely: Five Things Physicians and Patients Should Question. 2012. Available at: [Accessed April 6, 2012].
  13. 13.
    Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc. 2009;69:917–30. 930 e1.PubMedCrossRefGoogle Scholar
  14. 14.
    George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother. 2008;6:249–254.PubMedCrossRefGoogle Scholar
  15. 15.
    Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101:2200–2205.PubMedCrossRefGoogle Scholar
  16. 16.
    Bradley MC, Fahey T, Cahir C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol 2012.Google Scholar
  17. 17.
    Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19:1019–1024.PubMedCrossRefGoogle Scholar
  18. 18.
    Gosselin A, Luo R, Lohoues H, et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health. 2009;12:34–39.PubMedCrossRefGoogle Scholar
  19. 19.
    Hungin APS, Hill C, Molloy-Bland M, et al. Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:109–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Pillans PI, Kubler PA, Radford JM, et al. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust. 2000;172:16–18.PubMedGoogle Scholar
  21. 21.
    Abraham NS, Hartman C, Castillo D, et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol. 2008;103:323–32.PubMedCrossRefGoogle Scholar
  22. 22.
    El-Serag HB, Wieman M, Richardson P. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett’s oesophagus. Aliment Pharmacol Ther. 2008;27:1293–1299.PubMedCrossRefGoogle Scholar
  23. 23.
    El-Serag HB. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol. 2006;101:1727–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–18. quiz 1219.PubMedCrossRefGoogle Scholar
  26. 26.
    Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterol. 2005;129:1171–1178.CrossRefGoogle Scholar
  27. 27.
    Gurbel PA, Tantry US. Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. Nat Rev Cardiol. 2011;8:7–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther. 2006;24:377–385.PubMedCrossRefGoogle Scholar
  29. 29.
    El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009;104:2161–2167.PubMedCrossRefGoogle Scholar
  30. 30.
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  31. 31.
    Gadzhanova SV, Roughead EE, Mackson JM. Initiation and duration of proton pump inhibitors in the Australian veteran population. Intern Med J 2010.Google Scholar
  32. 32.
    Inadomi J, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98:1940–1944.PubMedCrossRefGoogle Scholar
  33. 33.
    Ostini R, Jackson C, Hegney D, et al. How is medication prescribing ceased? A Systematic Review. Medical Care. 2011;49:24–36.PubMedCrossRefGoogle Scholar
  34. 34.
    Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24:923–936.PubMedCrossRefGoogle Scholar
  35. 35.
    Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17:387–94.PubMedCrossRefGoogle Scholar
  36. 36.
    Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterol. 2008;135:1392–1413.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2013

Authors and Affiliations

  • Andrew J. Gawron
    • 1
    • 2
    • 3
  • John E. Pandolfino
    • 1
  • Scott Miskevics
    • 3
  • Sherri L. LaVela
    • 2
    • 3
  1. 1.Division of Gastroenterology & Hepatology, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  2. 2.Center for Healthcare Studies, Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  3. 3.Center for Management of Complex Chronic Care, Department of Veterans AffairsEdward Hines, Jr. VA HospitalHinesUSA

Personalised recommendations